Skeletal muscle involvement in antisynthetase syndrome

JAMA Neurology

Volumn 74, Issue 8, 2017, Pages 992-999

  Noguchi, Eri ^a   Uruha, Akinori ^b,c   Suzuki, Shigeaki ^a   Hamanaka, Kohei ^b   Ohnuki, Yuko ^d   Tsugawa, Jun ^e   Watanabe, Yurika ^a   Nakahara, Jin ^a   Shiina, Takashi ^d   Suzuki, Norihiro ^a   Nishino, Ichizo ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c SORBONNE UNIVERSITÉ   (France)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AMINOACYL TRANSFER RNA SYNTHETASE ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENZYME ANTIBODY; HLA DRB1 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; OJ ANTIBODY; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; AUTOANTIBODY;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTISYNTHETASE SYNDROME; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSPHAGIA; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HLA DRB1 GENE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; NECK MUSCLE; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR; SKELETAL MUSCLE; SYMPTOM; TISSUE NECROSIS; TREATMENT RESPONSE; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; ELECTROMYOGRAPHY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACYL-TRNA SYNTHETASES; AUTOANTIBODIES; COHORT STUDIES; ELECTROMYOGRAPHY; FEMALE; GENOTYPE; HLA-DRB1 CHAINS; HUMANS; IMMUNOPRECIPITATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 85027455349     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2017.0934     Document Type: Article

References (29)

1. Targoff IN Autoantibodies in polymyositis. Rheum Dis Clin North Am. 1992; 18(2):455-482.
2. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry. 2000; 68(4):472-478.
3. Stenzel W, Preuße C, Allenbach Y, et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology. 2015; 84(13):1346-1354.
4. Aouizerate J, De Antonio M, Bassez G, et al. Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun. 2014; 2:154.
5. Mescam-Mancini L, Allenbach Y, Hervier B, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain. 2015; 138(pt 9):2485-2492.
6. Dalakas MC Inflammatory muscle diseases. N EnglJ Med. 2015; 373(4):393-394.
7. De Bleecker JL, De Paepe B, Aronica E, et al.; ENMC Myositis Muscle Biopsy Study Group. 205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015; 25(3): 268-272.
8. Stenzel W, Goebel HH, Aronica E. Review: immune-mediated necrotizing myopathies: a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol. 2012; 38(7):632-646.
9. Suzuki S, Yonekawa T, Kuwana M, et al. Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. J Neuroimmunol. 2014; 274(1-2):202-208.
10. Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016; 87(10):1038-1044.
11. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988; 19(5):604-607.
12. Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 2012; 69(6):728-732.
13. Suzuki S, Satoh T, Yasuoka H, et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005; 170(1-2):141-149.
14. Ohnuki Y, Suzuki S, Shiina T, et al. HLA-DRB1 alleles in immune-mediated necrotizing myopathy. Neurology. 2016; 87(18):1954-1955.
15. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complexofaminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993; 91(6):2556-2564.
16. Meyer A, Lefevre G, Bierry G, et al.; Club Rhumatismes et Inflammation. In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome. Medicine (Baltimore). 2015; 94(20):e523.
17. Uruha A, Suzuki S, Suzuki N, Nishino I. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain. 2016; 139(pt 9):e50.
18. Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014; 73(1):227-232.
19. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013; 8(4):e60442.
20. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014; 13(4-5):367-371.
21. Nakashima R, Imura Y, Hosono Y, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 2014; 9(1):e85062.
22. Uruha A, Noguchi S, Hayashi YK, et al. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology. 2016; 86(3):211-217.
23. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016; 87 (3):299-308.
24. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016; 139(pt 8):2131-2135.
25. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and - DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006; 85(2):111-127.
26. Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012; 12(2): 210-217.
27. Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 2006; 54(6):2004-2009.
28. Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017; 88(5): 493-500.
29. Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015; 10:61.